Share on StockTwits

Horizon Pharma (NASDAQ:HZNP) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Thursday. They currently have a $11.00 price target on the stock. Zacks‘s target price suggests a potential upside of 29.26% from the company’s current price.

Several other analysts have also recently commented on the stock. Analysts at Piper Jaffray downgraded shares of Horizon Pharma from an “overweight” rating to a “neutral” rating in a research note on Tuesday. They now have a $9.00 price target on the stock, down previously from $22.00. Finally, analysts at Guggenheim initiated coverage on shares of Horizon Pharma in a research note on Friday, May 30th. They set a “buy” rating and a $31.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $18.14.

Shares of Horizon Pharma (NASDAQ:HZNP) traded down 4.49% on Thursday, hitting $8.51. The stock had a trading volume of 3,078,343 shares. Horizon Pharma has a one year low of $2.11 and a one year high of $18.30. The stock’s 50-day moving average is $14.61 and its 200-day moving average is $13.21. The company’s market cap is $625.2 million.

Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings data on Friday, May 9th. The company reported $0.16 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.01 by $0.15. The company had revenue of $51.90 million for the quarter, compared to the consensus estimate of $42.69 million. During the same quarter last year, the company posted ($0.36) earnings per share. Horizon Pharma’s revenue was up 496.6% compared to the same quarter last year. On average, analysts predict that Horizon Pharma will post $-1.57 earnings per share for the current fiscal year.

Horizon Pharma, Inc operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.